KIU Publications
Publications Archive
Explore research, reports, and scholarly works from the vibrant academic community at Kampala International University.
No matching results? Clear all filters to begin a fresh search.
Artemisinin-Based Combination Therapy: Emerging Evidence for Therapeutic Applications in Type 2 Diabetes Mellitus
Author: Otieno Karanja J.
Publisher: IDOSR JOURNAL OF BIOLOGY, CHEMISTRY AND PHARMACY
Published: 2026
Section: Faculty of Clinical Medicine and Dentistry
Abstract
Artemisinin and its derivatives, traditionally employed as antimalarial agents, had demonstrated pleiotropic
biological activities including anti-inflammatory, antioxidant, and metabolic regulatory properties. Recent
preclinical investigations suggested potential therapeutic applications beyond parasitic diseases, particularly in
metabolic disorders. This review critically evaluated the current evidence regarding the effectiveness of artemisinin
based combination therapies in managing type 2 diabetes mellitus in adult populations, examining molecular
mechanisms, experimental findings, and clinical implications. A comprehensive literature search of PubMed, Scopus,
and Web of Science databases was conducted for peer-reviewed studies published between 2014 and 2025
investigating artemisinin compounds and metabolic effects relevant to type 2 diabetes. Preclinical studies
demonstrated that artemisinin derivatives modulate glucose homeostasis through multiple mechanisms including
enhancement of pancreatic beta-cell function, improvement of insulin sensitivity via AMPK activation, reduction of
hepatic gluconeogenesis, modulation of inflammatory pathways, and mitigation of oxidative stress. Animal models
consistently showed reduced fasting glucose, improved glucose tolerance, and decreased insulin resistance following
artemisinin administration. Limited human studies suggest potential glycemic benefits, though robust clinical trial
data remain scarce. Combination approaches with conventional antidiabetic agents show synergistic effects in
experimental models. However, significant gaps exist regarding optimal dosing, long-term safety, and translation
of preclinical findings to clinical practice. While preclinical evidence supported potential antidiabetic properties of
artemisinin-based therapies, current clinical evidence is insufficient to recommend routine use in type 2 diabetes
management. Rigorous randomized controlled trials are urgently needed to establish efficacy, safety, and therapeutic
positioning.